Key step achieved in advancing HER-096 towards Phase 2 efficacy trial 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previous pre-clinica

Nov. 24, 2025 - Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the JS001sc-002-III-NSCLC study has met its primary endpoints. JS001sc-002-III-NSCLC is a multi-center, open-label, randomized Phase 3 clinical study comparing toripalimab injection (subcutaneous injection) (code: JS001sc) or toripalimab injection

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster dose No safety concerns observed in any age group by an independent Data Monitoring Committee (DMC) Results confirm benefits of a yearly vaccination prior to each Lyme season November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15

– Enlivex has adopted the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. – RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - built for transparency, automation, and community participation. – Mr. Matteo Renzi, former Prime Minister of Italy has joined the Enlivex Board of Directors. – Enlivex to continue clinical devel

Nov. 26, 2025 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present one oral late breaking communication and two poster presentations featuring blarcamesine at t

The Company expects to initiate first-in-human study in early 2026, with initial data anticipated H2 2026 Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi platform into clinical development Nov. 26, 2025 -- Tangram Therapeutics (‘Tangram’), a company committed to uniting computation and RNAi to make better medicines faster, today announced the submission of a Clinical Trial Application (CTA) to the Medicines and Healthcare products Regulatory Agency (

Nov. 25, 2025 -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company will host a virtual Key Opinion Leader Meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, including the combination with osimertinib in non-small cell l

Scilex closed the second tranche, purchasing a pre-funded warrant exercisable for 263,914,094 shares of Datavault AI Inc. (Nasdaq: DVLT; “Datavault AI”) common stock in Bitcoin (BTC) (based on the spot exchange rate of BTC as of the signing of the strategic investment). The closing followed the approval by the Datavault AI stockholders, obtained at Datavault AI’s November 24, 2025 annual meeting, of the issuance of the shares of Datavault common stock upon exercise of the pre-funded warrant. Sci

Nov. 26, 2025 -- Mural Oncology plc (Nasdaq: MURA) (“Mural”) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA Royalty”), XRA 5 Corp. (“Sub”) and Mural announced on August 20, 2025 (the “Transaction Agreement”), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash considera

Nov. 25, 2025 -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy. Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models co